Survodutide vs Semaglutide
Comparing Boehringer Ingelheim's dual GLP-1/glucagon agonist survodutide with single-target GLP-1 agonist semaglutide.
Last updated: February 1, 2026
Survodutide
Semaglutide
Overview
Survodutide (BI 456906) is Boehringer Ingelheim’s investigational dual GLP-1/glucagon receptor agonist, while semaglutide is an FDA-approved GLP-1 receptor agonist. Survodutide’s additional glucagon activity may offer enhanced metabolic benefits including greater effects on liver fat.
Mechanism Comparison
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Target Receptors | GLP-1 + Glucagon | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| Glucagon Effect | Agonist | None |
| Unique Feature | Liver-targeted metabolism | Proven CV benefit |
Why Glucagon Agonism?
Glucagon receptor activation may provide:
- Enhanced hepatic lipid oxidation
- Increased energy expenditure
- Greater reduction in liver fat
- Potential for MASH treatment
Evidence Comparison
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Development Phase | Phase 3 | FDA Approved |
| Human Trials | Multiple Phase 2/3 | Extensive (STEP, SUSTAIN, SELECT) |
| MASH Data | Positive Phase 2 | Limited |
| CV Outcomes | Not yet studied | SELECT trial positive |
Weight Loss Data
Phase 2 Obesity Trial Results
| Metric | Survodutide 4.8mg | Semaglutide 2.4mg (STEP 1) |
|---|---|---|
| Weight Loss | ~18-19% | ~15% |
| Trial Duration | 46 weeks | 68 weeks |
| Population | Obesity | Obesity |
Note: Cross-trial comparisons have limitations; head-to-head data not yet available.
MASH/NASH Focus
Survodutide has shown promising results for metabolic dysfunction-associated steatohepatitis (MASH):
| Outcome | Survodutide Phase 2 |
|---|---|
| MASH Resolution | Up to 83% (highest dose) |
| Fibrosis Improvement | Significant vs placebo |
| Liver Fat Reduction | Greater than GLP-1 alone |
This is a key differentiator - the glucagon component appears to provide enhanced liver benefits.
Regulatory Status
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| FDA Status | Investigational | Approved (Ozempic, Wegovy) |
| Indications | In development | T2D, Obesity, CV risk |
| MASH Pathway | Phase 3 ongoing | Not pursued for MASH |
| Expected Approval | TBD (2025-2026) | Already approved |
Side Effect Profile
| Effect | Survodutide | Semaglutide |
|---|---|---|
| GI Effects | Common (nausea, vomiting) | Common |
| Appetite Suppression | Strong | Strong |
| Heart Rate Increase | Observed | Observed |
| Hypoglycemia | Low risk | Low risk |
Glucagon’s hyperglycemic effect may partially offset GLP-1’s glucose-lowering, potentially affecting the diabetes indication.
Administration
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Route | Subcutaneous injection | SC injection + Oral |
Key Differences
- Dual mechanism: Survodutide adds glucagon agonism to GLP-1 effects
- Liver focus: Glucagon component drives enhanced liver fat reduction
- MASH indication: Survodutide being developed specifically for MASH
- Approval status: Semaglutide is approved; survodutide is investigational
- CV evidence: Semaglutide has proven cardiovascular benefit (SELECT trial)
Summary
- Survodutide offers dual GLP-1/glucagon mechanism with promising MASH data and potentially greater weight loss
- Semaglutide is FDA-approved with extensive safety data and proven CV benefit
- Glucagon agonism provides enhanced liver fat reduction but may complicate diabetes dosing
- Head-to-head trials would be needed to definitively compare efficacy
This comparison is for educational purposes only. Survodutide is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.